Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


INTERVIEW: Lupin head on US plans, fair biosimilar pricing and 'letting go'

This article was originally published in Scrip

Executive Summary

For those who've interacted with Lupin's founder chairman Dr Desh Bandu Gupta, his son Nilesh, who took over as managing director of the Indian pharma firm in September, is perhaps quite a contrast. Not that Dr Gupta ever held back, but Mr Gupta junior clearly represents India's young, ambitious and plain-speaking bosses, who are able to discuss both their company's successes and challenges, including some personal ones, with the same relative ease.


Related Content

Indian Avastin Biosimilar Arrives Amid Roche's Charges
Indian Avastin Biosimilar Arrives Amid Roche's Charges


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts